Study of LM11A-31-BHS in Mild-moderate AD Patients
Status:
Completed
Trial end date:
2020-06-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of 2 doses of LM11A-31-BHS in 180
patients with Alzheimer's Disease versus placebo and to access biomarker and clinical
exploratory endpoints of LM11A-31-BHS